Joined the holders in CBF this morning. Looks like a recovery going on here and I here whispers well speculation of new contract wins. The company seems to be moving away from DNA and focusing on protein and virus production and they seem to be far more focussed.

The company have restructured their sales and marketing team and appear to be more aggresive in their actions.

Fixed and variable costs have also been attacked and the company is working from a lower cost base. The companys order book is higher than it as been for a while and I beleive quarterly profit will be achieved.

Chart also looks strong and shows a break up.

Pointers To Recovery.

From last results 11th Jan.

Sales improvement in the second half of the financial year due to switch
from DNA to proteins and virus.



Restructuring of sales and marketing to address US market.



Restructuring of the Oxford and Keele facilities.



Broadening of customer base - 12 new customers in 2004.



The 4.8m Oxford Facility completed on time and to budget.



Contracted business for financial year 2005 stands at 2.7m.



Financial:


Revenue: H2 2004 up 30% to 2.0m compared with H1 2004 1.5m
FY 2004 down 42% to 3.5m (FY 2003: 6.0m)

Gross margin: H2 2004 49% compared with H1 2004 39%
FY 2004 45% (FY 2003: 57%)

Loss before tax: H2 2004 reduced by 17% to 1.03m compared with H1 2004 1.24m
FY 2004 2.27m (FY 2003: 0.82m profit)

Cash at bank: Sept 2004 3.2m compared with Mar 2004 3.8m (FY 2003: 7.3m)

Loss per share: FY 2004 12.3p (FY 2003: 6.9p earnings)

Director Speak

Commenting on the results, Peter Fothergill, Executive Chairman said:

'Our second half improvement and the current position of our order book are
significant achievements. Management moved rapidly during the year to focus
sales and marketing in the US and from DNA to virus and protein production. This
was no mean feat and we are cautiously optimistic for the future.'

Company Outlook Statement.

Management is actively seeking to broaden the customerbase particularly in the US biotechnology clusters and is examining ways toexpand the service offering including later stage manufacture and there by developing longer-term relationships which can reduce the impact of the high levels of clinical trials failure. These initiatives are already beginning to gain traction with contracted business currently 2.7 million for the financial year 2005 ('2005'), with 52% from North America. If this improvement continues Cobra will recover value for its shareholders.

Fundies.

Presently loss making but looks like the corner has been turned. Awaiting next trading update/results.

Beta.

Fairly High.

Conclusion

Highly Speculative, but the rewards if recovery does take place could be very rewarding.



cheers GF.

Chart showing the road to recovery.




The longer term picture.



cheers GF.

The road to recovery..................

8 February 2005





Cobra extends its agreement with Oncolytics Biotech Inc. to provide
long term manufacture of REOLYSIN(R)



Keele, UK, 8 February 2005 - Cobra Biomanufacturing Plc (AIM:CBF.L), the
international manufacturer of biopharmaceuticals, announces today that it has
extended its agreement with Oncolytics Biotech Inc. (NASDAQ: ONCY, TSX: ONC) to
provide additional cGMP production and clinical trial supply material of
REOLYSIN(R). This anticancer product is a proprietary formulation based on the
Reovirus and has shown promising results in Phase I clinical trials. The value
of the agreement is in excess of 750,000 for 2005.



David Thatcher, CEO of Cobra, said:

'I am delighted that we have been successfully re-appointed by Oncolytics
Biotech Inc. and we very much look forward to continuing our relationship. This
agreement further endorses our ability to both manufacture challenging viral
products, as well as build a North American customer base. We wish Oncolytics
every success in their next clinical trials and will do all we can by supplying
high quality product to meet their timelines.'



Brad Thompson, President and CEO of Oncolytics Biotech, commented:

'Advancing and expanding our human clinical trials in 2005 is driving our need
for further supply. We are pleased with the work done for us by Cobra to date,
and so going back to them for further, extended supply was an obvious decision.'

AND

For Immediate Release 11 February 2005




Cobra Biomanufacturing Plc

US Deal takes Order Book to 5.9m

Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of
biopharmaceuticals, today announces that the Company has concluded a major deal
with a US based biotechnology company. The value of the deal is in excess of
$3.6m and is a long term agreement covering the manufacture of eight protein
products.


This contract and other contracts concluded over the past month, move the value
of contracted business for the financial year 2005 to 4.9m (from 2.7m reported
in the January 11th Preliminary Results statement) and a total forward order
book value of 5.9m.


The Company's contracted business for the current financial year is 2.5 times
the position at this time last year. The composition of this business reflects
the refocusing of our sales effort towards virus and protein orders following
the shift in demand away from DNA. Protein products currently constitute 46% of
the current forward order book and virus 37%. Orders from the important North
American market contitute 72% of the current forward order book.


The directors believe that, following the refocusing of its sales
infrastructure, Cobra is regaining momentum and look to build further on
progress to date.

cheers GF.

Just moved up another penny.

cheers GF.

This one is too risky for me GF. I think I'll sit this one out for the time being. Not a good track record, but " He Who Dares". I think there are better one available at the moment.

LOL

MS

'YOUL BE SORRY'

Anyway back to business...............................

Cobra bites back with new US deal

Published: 16:16 Friday 11 February 2005
By: Graeme Davies, Investment Correspondent


Biopharmaceutical specialist Cobra Bio-Manufacturing has leapt 32% on news of a deal with a US biotech company that will boost its order book this year although investors still have some way to go to make up last year's losses.

The 9 million company (CBF) saw its shares slump from 150p to as low as 21.5p during 2004 as sales almost halved following the failure of DNA-based medicines in trials. Cobra makes experimental biotechnology drugs on behalf of other pharmaceutical companies for them to put through trials.

Cobra's shares have added 11.25p to 46.5p today after it announced a deal with an unnamed US biotech company. The value is in excess of $3.6 million (1.93 million) and will see Cobra manufacture eight protein products. This reflects management's attempts to widen its product range after a fall in demand for DNA-based products.

Cobra chief executive David Thatcher told Citywire: 'Things are going really well. This deal gives us a bit of stability going forward, normally our contracts have been 300,000-1 million. There is ten times as much investment into biotech in the US than the UK although the UK is still an important market. If the US dollar strengthens it will have a big impact on us.'

The latest deal takes the value of Cobra's contracted business for this year to 4.9 million and its total forward order book to 5.9 million. This means its contracted business is now worth two and a half times more than it had booked at this time last year. North American orders represent 72% of forward orders.

Last year turnover fell to 3.5 million and losses amounted to 2.3 million compared with a profit of 820,000 the previous year.

Today's deal is a bonus for Cobra investors and vindicates the management's broadening of its services but there is still a long way to go to recapture some of the excitement that surrounded the stock in late 2003 and early 2004.

One long term Cobra follower is AA-rated Paul Mumford of Cavendish Asset Management, who bought shares earlier this week and tried to buy more this morning but missed out before the shares shot up. He has been an active trader in Cobra, selling out his initial holding from its ML Laboratories demerger at Cobra's all time high.

Mumford told Citywire: 'This deal is good, it raises the level of orders and Cobra's order book is relatively short in terms of delivery time so it looks promising in terms of annual orders. Cobra has got a reasonably strong balance sheet, I always felt they could be taken out so it was a good two way bet but now it seems as though trading is going alright.'

Mumford's Cavendish Opportunities fund holds around 2% of Cobra.

cheers GF.

GF

I can't buy all you recommendations as the lolly is all invested. Your tips are outstripping the cash. Not that I'm complaining, long may it last. Decisions, decisions, decisions. Now what one will I buy next?

LOL

MS

CFDs that the answer Mickey. Anyway just heard Evil Knievil as gone LONG on these and says they have a solid balance sheet and are way undervalued.

cheers GF.

Some big buy volume this afternoon and the spread has tightened considerably. Nows the time to buy today.

cheers GF.

GF

Who do suggest for CFD'S?

MS

I was asking that myself over on the NLR thread, Eric, I dont know if has replied.

cheers GF.

Well GF I'm in, but not big time. I did'nt have time to do proper research so this one in a real punt for me. Talk about flying by the seat of your pants. I hope your right with this one.

LOL to both of us

MS

Nice to have you on board Mickey, just think your holding a share that the great bear Evil Knievil owns (LONG he is though).

cheers GF.

Oh no GF. Woman ( he shouts to wife in anixous voice) put the gas oven on I've just bought a share that Evil's got. Are you sure he's long?

MS

YES.

cheers GF. PS, do you realise it was him that gave out the tip, Gaming Corporation. Straight up. Hes often better at longs than he is shorts. He gave out a bio last week aswell that rocketed. Im just going to ring him now and see if he as any more tips.

Yes he as a tip, buy Cobra Bio Manufacturing.


Building up a lot of steam this one on other boards now. Should be a follow through effect.

cheers GF.

Momentum is certainly on the up, check out the trades all buys, superb.

cheers GF.

Buys pouring in.

cheers GF.

And its moved up and about time. Great recovery story this one.

cheers GF.

Long may it last. 1 by March.

MS

Look at the number of buys and they have only moved it up 1/2p. Skinny devils.

cheers GF.

No sells this morning. Tight sod's.

MS

Its the worst day all round Mickey I feel for over 2 weeks.

cheers GF.

The MMs owe me on this tomorrow.

cheers GF.

And they had better pay up.

cheers GF.

Unbeleivable, its down today by a penny. Think Ill add.

cheers GF.

what's your target price then GF, and do you think there are even more deals in the pipeline? It seems there's been a load of news recently, so we may not get any for a while, and hence a fall in the SP.

If you take yesterdays buys and add them to todays buys, buys far outweigh sells over the last couple of days. Dont really have a target I will leave that to the market mechanism. Just feel we are going to see them move up.

cheers GF.

This is a fantastic turnaround. Watch for new deals.

cheers GF.

Back to winning ways after yesterdays sell off. Looks like we got rid of the short term punters.

cheers GF.

More to come in the weeks ahead.

cheers GF.

Cobra Bio Manufacturing being used in new HIV/AIDS vaccine trail. 2p rise today.

This looks to be very good news, deals flowing all the time. Does this announcement suggest further revenues for CBF? if so the recovery is getting better by the day.

Moving ahead nicely.

Cobra Bio-Manufacturing technology being used in new HIV/AIDS vaccine trial
AFX


LONDON (AFX) - Cobra Bio-Manufacturing PLC said its proprietary DNA system has begun clinical evaluation as part of a new HIV/AIDS vaccine clinical trial funded by the European Union.

The Phase I trial is conducted by a consortium (Eurovacc) of organisations including Cobra and will be carried out initially in the UK and Switzerland.

newsdesk@afxnews.com


cheers GF.

EU trials for Cobra AIDS vaccine

Published: 12:11 Friday 18 February 2005 By: Douglas Bence, Companies Correspondent


Its revenue comes from a range of patented technologies, the most advanced of which are ORT(R), which avoids the use of antibiotics and antibiotic-resistant genes.

The word Eurovacc comes from the European Vaccine Effort against HIV/AIDS network, which is funded by the European Union

It is a non-profit organisation and has been working for five years with the aim of developing safe and effective preventive vaccines against HIV/AIDS.

At the point of injection, the patient's cells synthesize fragments of HIV proteins directed by the DNA vaccine, which triggers a powerful immune response against the virus.

The advantage of this approach is that the immune response can be focussed in such a way as to inhibit growth of the virus. Cobra shares added 1.5p to 49p.

Professors Hans Wolf and Ralf Wagner at the University of Regensburg developed the DNA-HIV-C vaccine.

It is based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing, and is designed specifically to combat strains of HIV/AIDS prevalent in Asia and sub-Saharan Africa.

Since its foundation in 1993, Cobra has specialised in DNA, virus and protein contract manufacture. It raised 7 million and floated on AIM in 2002.

Its revenue comes from a range of patented technologies, the most advanced of which are ORT(R), which avoids the use of antibiotics and antibiotic-resistant genes.

The word Eurovacc comes from the European Vaccine Effort against HIV/AIDS network, which is funded by the European Union

It is a non-profit organisation and has been working for five years with the aim of developing safe and effective preventive vaccines against HIV/AIDS.

This group has been working together for more than five years, and has developed a pipeline of potential vaccines.


cheers GF.

Just look at the volume going into this one. Me thinks good times ahead.

cheers GF.

I am thinking of selling Bioquell (done bugger all in three years) to get into this co. Will be watching carefully monday morning......... intersting products

already posted on another board and confirms news on the official IAVI website that COBRA are leading in the manufacture of trial DNA HIV vaccines.

http://www.iavi.org/viewfile.cfm?fid=8399

New trial of HIV/AIDS vaccine incorporates Cobra technology




http://www.cobrabio.com/


Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that its proprietary DNA system has begun clinical evaluation as part of a new HIV/AIDS vaccine clinical trial funded by the European Union.

The Phase I trial is conducted by a consortium (Eurovacc) of organisations including Cobra and will be carried out initially in the UK and Switzerland. The AIDS vaccine involves an initial injection with DNA, designed with the participation of Cobra and using Cobra's proprietary ORT DNA backbone and manufacturing technology.

The initial dose is then followed by a booster dose with a genetically engineered pox virus. The DNA-HIV-C vaccine was developed by Professors Hans Wolf and Ralf Wagner at the University of Regensburg based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing, and is designed to combat strains of HIV/AIDS prevalent in Asia and sub-Saharan Africa.

cheers GF.

And we still have further expansion of Cobra in the US to look forward to!

"Mr Thatcher said the company was looking to expand in the U.S. where it currently has offices in San Francisco and Chicago."

Sir Hugo Baskerville
i cannot get a link what does it say. TIA

Yes Sir Hugo sir, can you give us a snapshot?.

regards gf.

DRUGS FIRM IN 2M U.S. PROTEIN DEAL

RICHARD BABINGTON

12:00 - 16 February 2005

Drugs firm Cobra Manufacturing has secured a major deal worth almost 2 million with a U.S.-based biotechnology company. The 1.9 million contract, with an unnamed company, is a long-term agreement covering the manufacture of eight protein products.

It is the second boost within a week for the company, which employs 75 people at Keele Science Park.

Earlier this month, it announced that it had extended a contract to make a prototype anti-cancer treatment.

The deal, to continue supplying Reolysin to Oncolytics Biotech, is worth more than 750,000 this year.

Cobra chief executive, David Thatcher, said the deal was a breakthrough for the company, which announced heavy losses last month.

He said it showed how the company had transformed itself following its problems last year, moving away from DNA products and moving into the protein market.

He said: "The company was launched on the back of DNA technology, but DNA products are not approved - it's about research and development.

"Protein biopharmaceuticals is a major market for us. We're very pleased to get this contract: having a proven track record in America is essential."

Cobra reported a loss of 2.27 million last month, after sales fell 42 per cent.

But sales went up by 2 million in the second half of the year, after switching to meet demand for drugs using proteins and viruses rather than DNA.

Protein products now make up 46 per cent of Cobra's current forward order book, with virus products constituting 37 per cent.

Orders from the North American market now make up 72 per cent of the current forward order book.

Mr Thatcher said: "What caught us off guard last year, was a rapid decline in the DNA market, which lost us a lot of European business.

"In a perfect world we would have replaced DNA with protein faster."

The new contract has increased the value of contracted business for this financial year to 4.9 million, 2.5 times more than at this time last year.

Mr Thatcher said the company was looking to expand in the U.S. where it currently has offices in San Francisco and Chicago.
..............................................................................

Also from the Guardian 12/1/05

http://www.guardian.co.uk/business/story/0,,1388203,00.html

"He added that the firm is looking for strategic partners or potential merger and acquisition deals to broaden its capability still further."

Nicely up this morning on good volumes.

cheers GF.

From Hemscott..................

Cobra Biomanufacturing - Friday 18th February 2005

The loss-making biopharmaceuticals minnow saw its shares rise after revealing its DNA-making technology is being evaluated as part of an EU-funded HIV/AIDS vaccine clinical trial. The news is a boost for the group as its DNA business collapsed last year on falling demand. Kam Patel suggested the stock merited a speculative punt earlier this month, and now sticks by that call.


Cobra said the Phase I trial is being conducted by a consortium (Eurovacc) of organisations including Cobra and will be carried out initially in the UK and Switzerland. The AIDS vaccine involves an initial injection with DNA, designed with the participation of Cobra and using its proprietary DNA manufacturing technology.

The news is a boost for Cobra as it had a miserable time last year with the collapse of the DNA business. In its 2004 statement in January it reported that its sales had halved due to its pharma clients experiencing a large number of failures of trials using DNA based treatments, reducing demand for Cobra's DNA-making expertise.

In response, the company decided to heavily expand its capability for making proteins and viruses, where demand remains buoyant and deal newsflow has been very good.

More good news for its DNA business could come from, surprisingly enough, the Chancellor Gordon Brown. Earlier this year he put forward proposals that call for a doubling of public funding for research in HIV vaccines to 80m per annum.

Brown also wants to entice further industry and private equity investment in the area. He is expected to use Britains presidency of the G8 this year to implement a global effort in HIV vaccine research.


Brown also wants major industrialised countries to commit themselves to buying the first 300m vaccine courses at a cost of US$20 a course, so setting up a US$6bn
guarantee of a future market. Sav Neophytou, analyst at housebroker Seymour Pierce, says this could ensure further business investment, which currently stands at around 60m per year primarily by small biotechnology companies and university laboratories.

He points out though that although an HIV vaccine is the holy grail of infectious diseases, it also represents a very high risk strategy without significant proof of concepts and is viewed with a lot of scepticism by much of the scientific community.

Cobra Biomanufacturing is involved in the manufacture of seven experimental HIV vaccines. Increased funding for Cobras clients via initiatives being championed by Brown may allow for a recovery of its DNA business.

If Browns proposals are implemented, Neophytou reckons Cobras DNA revenues would grow by 30%, although he stresses the product candidates that Cobra has an interest in are very early stage and very high risk. He is currently not factoring them in to his forecasts.

As we pointed out earlier this month, Cobra has managed to drastically reduce its reliance on DNA by expanding its protein and virus making capacity. Deal newsflow for the latter two is expected to be good going forward, especially from the key US market.

Today's news then is welcomed as it provides some support for a part of Cobra's business that has been through the mill. But it is extremely early days as regards the possibility of the EU-backed trials coming up with a successful vaccine. If Brown manages to deliver with his proposals, it could make things even more interesting for Cobra's DNA business.

The full-year consensus forecast is for a pretax loss of 450,000, and a loss in earnings per share of 2.02p. Cobra is projected to move back into the black next year with full year 2006 pretax profits seen coming in at 170,000, with earnings per share of 0.94p.

In the wake of the statement Cobra's shareprice rose 3p to 50p. Still a speculative buy.

An earlier article aswell from Hemscott, note the broker comments........

Cobra Biomanufacturing -Friday 11th January 2005

The biopharmaceuticals group's shares jumped after it announced it has won a 3.6m protein manufacturing contract. Cobra had an awful 2004 after the collapse of its DNA business but a new focus on protein and virus product manufacturing looks like it is beginning to pay off. It is well worth a speculative flutter, says Kam Patel.


--------------------------------------------------------------------------------

The new deal will cover the manufacture of eight proteins for a US-based biotechnology company. Cobra says the contract, along with others concluded over the past month, takes the value of its contracted business for the 2005 financial year to 4.9m from the 2.7m it reported in its full statement of January 2005. The total value of its forward order books stands at 5.9m.

The fresh momentum in its business follows the collapse of its DNA business last year. In its full year 2004 statement in January it reported that its sales had halved due to a large number of failures of trials using DNA based treatments, reducing demand for Cobra's DNA making expertise.

In response, the company decided to heavily expanded its capability for making proteins and viruses, where demand remains buoyant.


Protein products now account for 46% of its current forward order book while virus products make up 37%. Orders from the key North American market constitute 72% of the current forward order book, it said today.

[b]Seymour Pierce analyst Sav Neophytou says today's announcement could provide upside to his full year 2005 revenue forecast of 7.3m. He is confident there will be further good deal newsflow over the year, especially from the US, and says the company may even manage to breakeven this year, ahead of his expectations of a move into the black in 2006.[/b]

cheers GF.

Should maintain momentum and move further north.

cheers GF.

Out of all my holdings this is the one I feel least confident about. Give me some assurance someone.

MS

Watch out for news in shares Mag and IC this week. Remember all the good stuff came out after these had gone to print last week.

cheers GF.

Ps, thought you said you werent going into this one? too risky I think you said.

GF, what makes you sure there will be news in the mags this week regarding CBF
cheers

It was your Midas touch that persuaded me GF. You other tips have come good so I thought this one would be the same. Please keep posting on this one, just to keep me from having a nervious breakdown.

LOL

MS

HM, because they have followed it closely before even when it was under the cosh. You usually have financial journalists with a portfolio of shares who tend to update on those in their portfolio just like ourselves out on the boards.
Fingers crossed it doesnt always run to form but it quite often does, hope that makes sense. Another tip, on tip sheets look out for the news at the back that as come late and they can only give it a few lines. Sometimes month after it is the main tip.

Mickey, futures in US are well down, get your bottle of Whisky out for this afternoon. Better still Meths.

cheers GF.

Not hit that hard today, less than a penny.

cheers GF.

Dont sell off, the markets getting a shock taste of reality. There will be a bounce in the US.

cheers GF.

Just out from Killik brokers....................

Sentiment in the near term appears to have turned with active profit taking in the second liners after a terrific run to the start of the year. How far things will come back is the obvious key question but so far, it does not appear as if too much stock is coming out and this feels more like a healthy correction rather than something more significant.

cheers GF.

Holding its ground pretty well.

cheers GF.

Continuing talk on other boards of a new deal. Seems to be recovering very well.

cheers GF.

Good result with another new deal GF, seems like CBF are really motoring after the change in direction. Any ideas on how much the new deal is worth to CBF? If it sees them into profit at next results this could be a real turning point.

Snaylor,
It seems the terms and value of the agreement were not disclosed.
See link below.
http://www.iii.co.uk/news/?type=afxnews&articleid=5221085&action=article

Yup excelent new deal. and stock already up 13%, news delivered right on cue.


Cobra Bio-Manufacturing PLC
25 February 2005


For Immediate Release 25 February 2005



Cobra signs long term deal with Neovacs SA to supply Phase I clinical trial
material for a novel protein active immunization therapy-TNFa Kinoid



Keele, UK, 25 February 2005 - Cobra Biomanufacturing Plc (AIM:CBF.L), the
international manufacturer of biopharmaceuticals, announces today that it has
signed a long term manufacturing agreement with Neovacs SA to supply clinical
trial material for a protein biopharmaceutical, TNFa Kinoid. This novel active
immunization therapy against the human cytokine, Tumour Necrosis Factor a
(TNFa), will be tested for its efficacy in auto-immune and inflammatory
diseases. The terms and value of the agreement were not disclosed.



Overproduction of protein cytokines, such as TNFa, is the cause of many
inflammatory diseases. Neovacs Kinoid technology involves inactivating cytokines
and conjugating them to a carrier. The resulting cytokine protein complex
(Kinoid) serves as an active immunization therapy that induces a natural and
potent antibody response by the patient's immune system. This enables the
harmful cytokines to be neutralised and the disease treated. In addition to TNFa
Kinoid, Neovacs is developing other active immunization therapies against
numerous human cytokines to treat a range of diseases.



Alain Huriez, CEO of Neovacs, commented:



'We were impressed with Cobra's expertise and track record in protein process
development. We feel confident that Cobra will deliver us quality Kinoids on
schedule for our Phase I clinical trials.'



David Thatcher, CEO of Cobra, said:



'We are pleased to be selected by Neovacs to produce this novel cytokine protein
complex for European clinical trails. This long term agreement recognises
Cobra's expertise in producing emerging protein therapies and vaccines.'




-Ends-

cheers GF.

anyone got any recent broker feedback re revised forecasts, eps and price targets - am inclined to believe further significant recovery is on the cards now, back to 100p hopefully. co seems to be developing strong momentum. Mind you I did buy sometime ago and am still nursing losses but management are performing and as I said I think there is still some way to go for now. enjoy the ride and dyor.

Im waiting for Evolution to produce a note, as soon as its out Ill post it. I agree with you Recovery is now well under way.

cheers GF.

looking good now.Has broken clear of the upper trend line,although not correct has a GOLDEN CROSS that didnt break down.
NORTH FOR CHRISTMAS

Is MLB Plc connected to this company still?

No,they sold out their share in Dec.2003.MLB looks to be an interesting play soon re:clickhaler approval soon.Ethel

thanks ethel. I agree, good things are happening now with mlb

troys

Stop dithering and get in.

Further speculative gossip this weekend, more contracts coming through.

Hold on to your seats.


cheers GF

On a roll now this one. Just added myself again this morning.

cheers GF.

Still positive, just.

cheers GF.

A resiliant little devil this one.

cheers GF.

A down day across all the small cap board, not company specific. No reason to sell.

cheers GF

Looking for an up day WED after the Yank close tonight.

cheers GF.

I am so impatient - terrible for trading - however a mid term hold on this will bring a few smiles - I expect it to be 80p within 5 and a half weeks :)

Recovery on the way on the back of new contract wins. Nice to see higher volume levels.



cheers GF.

it would appear we have another contract

http://www.cobrabio.com/prs/020305.htm

Company

Business development

Custom manufacture

Vector technologies

Investor relations

Contact

News

Exhibitions

2 March 2005

Cobra signs agreement with Hawaii Biotech Inc to manufacture two novel protein vaccines against Dengue fever and West Nile disease for US clinical trials

Cobra Biomanufacturing Plc (London Stock Exchange AIM), has announced that it has signed an agreement with Hawaii Biotech, USA, to manufacture and supply material for clinical trials of vaccines against Dengue fever and West Nile disease. The financial terms and conditions of the agreement were not disclosed.

Hawaii Biotechs vaccine technology is based on the production of proprietary genetically engineered antigens (proteins) that produce immune responses equivalent to or better than traditional live or inactivated virus approaches. The Dengue vaccine product consists of an adjuvant and five viral proteins which have been cloned and expressed in insect cells. The West Nile vaccine product consists of a single recombinant protein and adjuvant. The vaccines potentially have a significantly improved safety profile compared to traditional approaches.

Dengue fever and West Nile disease are growing problems in North America. Dengue fever is expanding globally with an estimated 50 million to 100 million cases of Dengue worldwide annually, with more than 20,000 deaths. Caused by a virus that is carried by mosquitoes it produces severe flu-like symptoms that can lead to a life threatening haemorrhagic fever. Unknown in North America until 1999, the West Nile virus is now permanently established throughout this territory. A significant cause of human illness in the US from 2002, its most serious manifestation is fatal encephalitis (inflammation of the brain). West Nile virus also causes disease in numerous wild and domestic animal species.

Commenting on the agreement, Dr David Thatcher, CEO Cobra said: "This is a significant program for Cobra and we are thrilled to have been selected by Hawaii Biotech. Todays announcement is a valuable endorsement of our ability to manufacture protein vaccine products for US clinical trials and demonstrates our continued ability to penetrate the North American biopharmaceutical market."

David G. Watumull, President and CEO, Hawaii Biotech added: "Hawaii Biotech,Inc is pleased to enter this collaboration with Cobra Biomanufacturing Plc. for the cGMP manufacture of our Dengue and West Nile recombinant subunit vaccine candidates. This is an important step in the preclinical development of these vaccines and critical to the successful launch of our anticipated Phase 1 clinical trials for both Dengue and West Nile vaccines in 2006. We have been impressed by the experience Cobra brings to the table and look forward to a mutually beneficial collaboration."

- ENDS -

For further information, please contact:

David Thatcher, Chief Executive Officer
Cobra Biomanufacturing Plc
Tel: +44 (0) 1782 714 181

David G. Watumull, President and CEO
Hawaii Biotech, Inc.
+1 808 486 5333

Media enquiries:
Eileen Paul
Northbank Communications
Tel: +44 (0) 1260 296500

Back




Design byNorthbank Communications

Excelent news.

cheers GF.

What does everyone make of the fall in SP over the last few days. You cant really expect more positive newsflow than Cobra keep delivering!

Strange to say the least. Perhaphs it just stale bulls unloading.

cheers GF.

intresting!

http://biz.yahoo.com/prnews/050304/to266_1.html

COBRA should be announcing a quarterly trading statement on 7th April at the time of the AGM.
more upside on the run up?

Lets hope so alderley, the share price as been poor and confusing to say the least over the last few days.

cheers GF.

gf
i'm going to be getting some more,possibly the dip is due to no RNS on the recent contract and somebody taking advantage(as if they would).Bounced off our low today so IMHO.
good luck

DRUGS FIRM'S 1.9M BOOST FROM U.S. DEAL

RICHARD BABINGTON

12:00 - 09 March 2005

A Drugs firm has continued its successful start to the year by signing a deal with a Hawaiian company worth almost 1.9 million. Cobra Biomanufacturing, which is based at Keele Science Park, has signed an agreement with Hawaii Biotech to make and supply material for clinical trials of vaccines against Dengue fever and West Nile disease.

The two diseases are growing problems in North America. Cases of Dengue fever are increasing worldwide, with up to 100 million cases annually and more than 20,000 deaths.

It is caused by a virus carried by mosquitoes and produces severe flu-like symptoms that can lead to a life-threatening haemorrhagic fever.

The West Nile virus was unknown in North America until 1999, but it is now prevalent throughout the region.

In serious cases it can lead to fatal inflammation of the brain. It can also cause disease in numerous wild and domestic animal species.

It is the second large U.S. deal that Cobra has signed within a month. The company won another contract worth more than 1.8 million in February.

The contracts have come after Cobra decided to move towards virus and protein orders because of a fall in demand for DNA products.

In January, the company reported a loss of 2.27 million after sales fell 42 per cent.

But it saw an improvement in the second half of the year when sales went up to 2 million, which it put down to the switch to protein and virus products.

Cobra's chief executive Dr David Thatcher said: "

Today's announcement is a valuable endorsement of our ability to manufacture protein vaccine products for U.S. clinical trials and demonstrates our continued ability to penetrate the North American biopharmaceutical market."

David Watumull, president and chief executive of Hawaii Biotech,

said: "We have been impressed by the experience Cobra brings to the table and look forward to a mutually beneficial collaboration.

Excelent research that.

cheers GF.

missed that bit Lol!

See cross reference to CBF on Post 16 ELA.
sd.

Got out at 53, just as well.

MS

Its been a cracking day for this one.

cheers GF.

Mickey jumped ship to quick he should of had more faith.
DB66

Any share that has EK in gets me spooked. Took my money and topped up MMG. Now tell me I made a mistake, I don't think so. This share has a real bad track record. OK things may have changed. If it really does start to happen I can always get back in.

LOL and have a good week end.

MS

Fair enough, have a good weekend yourself and lets all have a drink or two for MMG and Goldfinger and roll on Monday.
DB66

RNS Number:0853K
Cobra Bio-Manufacturing PLC
23 March 2005


For Immediate Release 23 March 2005


COBRA BIOMANUFACTURING PLC

PRE-CLINICAL DATA SUPPORTS POTENTIAL OF COBRA'S PROPIETARY ORT-VAC ORAL
BACTERIAL VACCINE

Keele, UK: Cobra Biomanufacturing plc (AIM: CBF), the international manufacturer
of biopharmaceuticals, today announces the results of a five year research
collaboration with the UK Ministry of Defence agency dstl, (Defence Science and
Technology Laboratory), Porton Down, UK, on the development of an improved
approach to oral vaccination that avoids the risks of using antibiotics or
antibiotic-resistance genes.

Comparison of the ORT-VAC system with conventional bacteria vaccine strains show
that, post administration, the ORT VAC product is stable and the conventional
strains highly unstable. In other experiments reported in the same paper, using
a rigorous plague challenge model in rodents, proof-of-principle results
published today show that a single oral dose vaccine achieved a high level of
immunity against plague.

The results of this research collaboration are published today in the
prestigious peer reviewed journal Infection and Immunity (Volume 73, Issue: 4
Page 2005), published by the American Society of Microbiology. http://
iai.asm.org/cgi/content/abstract/73/4/2005

Commenting on the results, Dr David Thatcher, Cobra's CEO, said:

"Cobra's scientists are renowned for their innovative approaches. Results from
this publication could represent a breakthrough in vaccine strain development as
they clearly demonstrate that ORT-VAC technology will allow the production and
oral delivery of stable strains carrying a high number of copies of the vaccine
gene per cell and therefore ORT-VAC strains are likely to have increased potency
compared with conventional strains.

The results also show that approaches to the development of high potency oral
vaccine strains, using conventional molecular biology, lead to strains which
rapidly lose their component antigen genes after administration and therefore
are potentially less effective compared with the fully stabilised ORT-VAC
vaccines. ORT-VAC approach avoids use of live bacteria which are antibiotic
resistant and carry a serious potential of generating antibiotic resistant
infection."

The ORT-VAC technology allows easy oral administration and cost effective
manufacture of vaccines. It is readily applicable to convert any suitable
bacteria strain to an antibiotic-free ORT strain for DNA and recombinant protein
vaccine delivery in humans. Recombinant protein vaccines are becoming
increasingly important as a prophylaxis and as a therapy. ORT-VAC vaccines will
have applications in cancer, HIV/Aids and tuberculosis as well as newly emerging
diseases, such as avian flu. It will also have utility against diseases such as
anthrax posed by the threat of bioterrorism.

For further information please contact:

David Thatcher Cobra Biomanufacturing + 44 (0) 1782 714181
Chief Executive Officer

Mark Court/Rebecca Skye Dietrich Buchanan Communications + 44 (0) 207 466 5000

Eileen Paul Northbank Communications + 44 (0) 1260 296500


Notes To Editors:

About Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.

Cobra was the first company to develop and gain GMP (Good Manufacturing
Practice) standard DNA manufacture in Europe, with specific expertise in DNA
medicines. A range of unique, patented technologies, underpins this revenue
generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising #7 million and raised a further #5.2 million in May 2003 in
order to further expand capacity in Oxford UK.

www.cobrabio.com

ORT(R) Technology is a way of creating totally stable genetically engineered
strains of micro-organisms without the use of antibiotics or antibiotic genes.
Other technologies rely on either integrating the synthetic gene(s) into the
bacterial chromosome or using antibiotics and antibiotic resistance genes to
amplify replicating mini-chromosomes (called plasmids) containing the new genes.
In the vaccine field it has been known for 10 years that the former approach
leads to poor strain productivity and the latter to strain instability. Use of
antibiotics also creates the risk of passing on the antibiotic resistance genes
to pathogens in the environment. Such events have occurred naturally to create
MRSA super bug strains so ORT(R) strains are inherently safer for patients.
ORT(R) technology avoids these problems.

Live Oral Vaccines are vaccines where the active agent is a live organism and is
taken orally. Live vaccines have been based on attenuated strains of the
disease-causing organism and historically this approach has been particularly
effective in inducing protection against disease (e.g. BCG for tuberculosis).
Attenuated live strains of Adenovirus and Salmonella have been used as oral
vaccines against respectively respiratory illness and typhoid caused by the
virulent parental strains. The advent of genetic engineering means that bacteria
such as Salmonella can be genetically modified to carry new traits that can
protect against a chosen disease not only diseases of the gut.

ORT-VAC Technology harnesses the advantages of conventional genetic engineering
with the safer ORT(R) strain stabilisation technology. ORT-VAC allows rapid and
simple construction of bacterial vaccine strains, capable of expressing massive
quantities of synthetic antigenic proteins that can lead to protection against
disease without the fear of creating antibiotic resistant strains which might be
difficult to manage clinically. ORT-VAC technology can potentially be used to
protect both against common infectious diseases such as meningitis, new diseases
such as Avian Flu, old diseases posing a new threat such as those which could be
used by terrorists and also cancer.

Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements. In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'. Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research, which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.


This information is provided by RNS
The company news service from the London Stock Exchange

Nice to see this on the move Mickey had me worried when he said EK was in this.Thanks for the post Alder looks promising.
DB66

Evils in it LONG not short.

cheers GF.

Thanks Goldfinger, in that case welcome aboard Evil.
db66

a snipit from the AFX

ORT-VAC vaccines will have applications in cancer, HIV/Aids and tuberculosis as well as newly emerging diseases, such as avian flu, Cobra added, and will will also have utility against diseases such as anthrax posed by the threat of bioterrorism.

looking very good

Ping!

going up strongly.

GREAT NEWS! It will be the next MMG

UK smallcap opening - Cobra Bio up on vaccine press comment
AFX


LONDON (AFX) - Shares in Cobra Bio-Manufacturing, firm yesterday following the publication of a positive study, moved up 6-1/2 pence more to 64-1/2 after press comment suggesting that major drugs firms will now be knocking on the door.

The study showed that pre-clinical data supports the potential of the biopharmaceutical maker's proprietary Ort-Vac oral bacterial vaccine.

positive stuff - should see 100p again this year. story taking shape and prospects improving all the time.

Superb news.

cheers GF.

hlyeo98 nice one,good rise again today and hopefully over the weekend we should see some more press coverage.i think todays article was in the Mail.

Thank you, Alderleyedge, with MMG and CBF and VML, they are winners. Have a good Easter, Alderley.

hyleo have a good one yourself,
here is the mail article

ANALYSTS reckon that major drugs firms will now be knocking on the door of
Cobra Biomanufacturing.It follows the publication of a study showing that pre clinical data supports the potential of the biopharmaceutical makers proprietary Ort-Vac oralbacterial vaccine.Dealers also expect the trading statement on 7th April to confirm that Cobra is now in the best of health.
Shares rose 5.75 to 58p

CBF a company with great potential...

23 March 2005
Pre-clinical Data Supports Potential of Cobra's Proprietary ORT-VAC Oral Bacterial Vaccine
Cobra Biomanufacturing plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces the results of a five year research collaboration with the UK Ministry of Defence agency dstl, (Defence Science and Technology Laboratory), Porton Down, UK, on the development of an improved approach to oral vaccination that avoids the risks of using antibiotics or antibiotic-resistance genes.
Comparison of the ORT-VAC system with conventional bacteria vaccine strains show that, post administration, the ORT VAC product is stable and the conventional strains highly unstable. In other experiments reported in the same paper, using a rigorous plague challenge model in rodents, proof-of-principle results published today show that a single oral dose vaccine achieved a high level of immunity against plague.
The results of this research collaboration are published today in the prestigious peer reviewed journal Infection and Immunity (Volume 73, Issue: 4 Page 2005), published by the American Society of Microbiology [http://iai.asm.org/cgi/content/abstract /73/4/2005]
Commenting on the results, Dr David Thatcher, Cobras CEO, said: Cobras scientists are renowned for their innovative approaches. Results from this publication could represent a breakthrough in vaccine strain development as they clearly demonstrate that ORT-VAC technology will allow the production and oral delivery of stable strains carrying a high number of copies of the vaccine gene per cell and therefore ORT-VAC strains are likely to have increased potency compared with conventional strains.
Continuing Dr Thatcher says: The results also show that approaches to the development of high potency oral vaccine strains, using conventional molecular biology, lead to strains which rapidly lose their component antigen genes after administration and therefore are potentially less effective compared with the fully stabilised ORT-VAC vaccines. ORT-VAC approach avoids use of live bacteria which are antibiotic resistant and carry a serious potential of generating antibiotic resistant infection.
The ORT-VAC technology allows easy oral administration and cost effective manufacture of vaccines. It is readily applicable to convert any suitable bacteria strain to an antibioticfree ORT strain for DNA and recombinant protein vaccine delivery in humans. Recombinant protein vaccines are becoming increasingly important as a prophylaxis and as a therapy. ORT-VAC vaccines will have applications in cancer, HIV/Aids and tuberculosis as well as newly emerging diseases, such as avian flu. It will also have utility against diseases such as anthrax posed by the threat of bioterrorism.


2 March 2005
Cobra signs agreement with Hawaii Biotech Inc to manufacture two novel protein vaccines against Dengue fever and West Nile disease for US clinical trials
Cobra Biomanufacturing Plc (London Stock Exchange AIM), has announced that it has signed an agreement with Hawaii Biotech, USA, to manufacture and supply material for clinical trials of vaccines against Dengue fever and West Nile disease. The financial terms and conditions of the agreement were not disclosed.
Hawaii Biotechs vaccine technology is based on the production of proprietary genetically engineered antigens (proteins) that produce immune responses equivalent to or better than traditional live or inactivated virus approaches. The Dengue vaccine product consists of an adjuvant and five viral proteins which have been cloned and expressed in insect cells. The West Nile vaccine product consists of a single recombinant protein and adjuvant. The vaccines potentially have a significantly improved safety profile compared to traditional approaches.
Dengue fever and West Nile disease are growing problems in North America. Dengue fever is expanding globally with an estimated 50 million to 100 million cases of Dengue worldwide annually, with more than 20,000 deaths. Caused by a virus that is carried by mosquitoes it produces severe flu-like symptoms that can lead to a life threatening haemorrhagic fever. Unknown in North America until 1999, the West Nile virus is now permanently established throughout this territory. A significant cause of human illness in the US from 2002, its most serious manifestation is fatal encephalitis (inflammation of the brain). West Nile virus also causes disease in numerous wild and domestic animal species.
Commenting on the agreement, Dr David Thatcher, CEO Cobra said: "This is a significant program for Cobra and we are thrilled to have been selected by Hawaii Biotech. Todays announcement is a valuable endorsement of our ability to manufacture protein vaccine products for US clinical trials and demonstrates our continued ability to penetrate the North American biopharmaceutical market."
David G. Watumull, President and CEO, Hawaii Biotech added: "Hawaii Biotech,Inc is pleased to enter this collaboration with Cobra Biomanufacturing Plc. for the cGMP manufacture of our Dengue and West Nile recombinant subunit vaccine candidates. This is an important step in the preclinical development of these vaccines and critical to the successful launch of our anticipated Phase 1 clinical trials for both Dengue and West Nile vaccines in 2006. We have been impressed by the experience Cobra brings to the table and look forward to a mutually beneficial collaboration."


25 February 2005
Cobra signs long term deal with Neovacs SA to supply Phase I clinical trial material for a novel protein active immunization therapy-TNFa Kinoid
Cobra Biomanufacturing Plc (AIM:CBF.L), the international manufacturer of biopharmaceuticals, announces today that it has signed a long term manufacturing agreement with Neovacs SA to supply clinical trial material for a protein biopharmaceutical, TNFa Kinoid. This novel active immunization therapy against the human cytokine, Tumour Necrosis Factor a (TNFa), will be tested for its efficacy in auto-immune and inflammatory diseases. The terms and value of the agreement were not disclosed.
Overproduction of protein cytokines, such as TNFa, is the cause of many inflammatory diseases. Neovacs Kinoid technology involves inactivating cytokines and conjugating them to a carrier. The resulting cytokine protein complex (Kinoid) serves as an active immunization therapy that induces a natural and potent antibody response by the patients immune system. This enables the harmful cytokines to be neutralised and the disease treated. In addition to TNFa Kinoid, Neovacs is developing other active immunization therapies against numerous human cytokines to treat a range of diseases.
Alain Huriez, CEO of Neovacs, commented: We were impressed with Cobras expertise and track record in protein process development. We feel confident that Cobra will deliver us quality Kinoids on schedule for our Phase I clinical trials.
David Thatcher, CEO of Cobra, said: We are pleased to be selected by Neovacs to produce this novel cytokine protein complex for European clinical trails. This long term agreement recognises Cobras expertise in producing emerging protein therapies and vaccines.


18 February 2005
New trial of HIV/AIDS vaccine incorporates Cobra technology
Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that its proprietary DNA system has begun clinical evaluation as part of a new HIV/AIDS vaccine clinical trial funded by the European Union.
The Phase I trial is conducted by a consortium (Eurovacc) of organisations including Cobra and will be carried out initially in the UK and Switzerland. The AIDS vaccine involves an initial injection with DNA, designed with the participation of Cobra and using Cobras proprietary ORT DNA backbone and manufacturing technology.
The initial dose is then followed by a booster dose with a genetically engineered pox virus. The DNA-HIV-C vaccine was developed by Professors Hans Wolf and Ralf Wagner at the University of Regensburg based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing, and is designed to combat strains of HIV/AIDS prevalent in Asia and sub-Saharan Africa.

moving along nicely again today!

We seem to be a very small crowd on this thread.Too many people burnt already by this share,maybe.But the news is very exciting.Feel sp would like to rise a lot,but kept back by general pessimism in markets.The chart looks good for a nice ascendancy,first resistance at 75p,if breached on to 90p.Hope this comes to pass!!
Ethel

I dont think this share will have as much in it as 90p for at least 9 to 12 months. Although there have been press reports nothing positive has come out as far as rnx for the company will hover around the 70p for the imminent time being. Im not interested in this share as yet will wait a while unti all the profit takers have finished then re assess over the coming weeks. There are profits to be had elsewhere. Good luck to those holding

I'm with you Bankone, but it's on my radar screen. EK is in this one but GF says he's long. That doesn't instill me with confidence.

LOL

MS

Well here it is - GOOD NEWS - Revise my Post 90p by end of month.

Cobra Bio-Manufacturing PLC
07 April 2005


For Immediate Release 7 April 2005

Cobra Biomanufacturing Plc

AGM Statement/Trading Update


Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of
biopharmaceuticals, held its AGM today and made the following statement on
trading for the six months to 31 March 2005.

'Cobra has had a positive six months ('H1 2005') and is currently trading well.
Revenue for H1 2005 is up 50% from the previous six months to 3.0m and the
opening contracted business for the second half of the financial year
('H2 2005') is 2.8m.

'Our change of focus from the smaller DNA market to the manufacture of virus and
the much larger market for proteins has been very effective; protein contracts
now account for 48% and virus contracts for 33% of our contracted business for
financial year 2005. Additionally focusing our sales efforts on the publicly
listed biotechnology companies in North America is also proving to be very
successful and this market now represents 75% of the current year's order book,
including part of a long term contract worth in excess of $3.6m.

'The overall business environment continues to improve, and the company is
competing well as demonstrated by the number of important contracts announced
since the beginning of the calendar year.'

All resolutions at the AGM were passed.


For further information:

Cobra Biomanufacturing Plc Tel: 44 (0) 1782 714 181
David Thatcher, Chief Executive

Buchanan Communications Tel: 44 (0) 20 7466 5000
Tim Anderson/Mark Court/Rebecca Dietrich


About Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.

Cobra was the first company to develop and gain GMP (Good Manufacturing
Practice) standard DNA manufacture in Europe, with specific expertise in DNA
medicines. A range of unique, patented technologies, underpins this revenue
generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising 7 million and raised a further 5.2 million in May 2003 in
order to further expand capacity in Oxford UK.

www.cobrabio.com

Thanks for that Bankone, a really positive statement and seems to bode well for the future even with EK in this.
DB66

Evils long on it DB. Strange but have a look at the trades after the AGM?????????????????????????????????????????., ie after the 11.15 am announcement look to be all sells . Have I missed some news whilst on holiday or where investors expecting more from the company ?????????????.

cheers GF.

Cobra Bio-Manufacturing says H1 positive, sales up 50 pct vs previous 6 mths
AFX


LONDON (AFX) - Cobra Bio-Manufacturing PLC said it has had a 'positive' six months and is currently trading well.

Revenue for the first half of 2005 is up 50 pct from the previous six months to 3.0 mln stg and the opening contracted business for the second half of the financial year is 2.8 mln.

'Our change of focus from the smaller DNA market to the manufacture of virus and the much larger market for proteins has been very effective; protein contracts now account for 48 pct and virus contracts for 33 pct of our contracted business for financial year 2005,' the company said.

'Additionally focusing our sales efforts on the publicly listed biotechnology companies in North America is also proving to be very successful and this market now represents 75 pct of the current year's order book, including part of a long term contract worth in excess of 3.6 mln usd.'

The company added: 'The overall business environment continues to improve, and the company is competing well as demonstrated by the number of important contracts announced since the beginning of the calendar year.'

bam

I think cobras held up quite well considering the amount of sells in recent
days.
http://biz.yahoo.com/prnews/050407/to286.html?.v=2

Goldfinger are you sure Evil hasn`t changed his mind? i`m sitting on a small profit and don`t want to lose like i did in MMG. Evil`s getting his arse kicked with SEO so i am wondering if his turning his attention to CBF.
db66

DB he closed down Stanelco last week. Hes certainly long of Cobra and not the other way round.

Nice rise in these aswell today. Good day all round.

cheers GF. PS PM for you.

Well at least this was positive today.

cheers GF.

Holding steady again at the moment,but 150,000 sell has just
gone through and for Cobra that is a big amount!
DB66

RNS Number:8185L
Cobra Bio-Manufacturing PLC
04 May 2005


For Immediate Release 4 May 2005


Cobra Biomanufacturing and Synco BioPartners form alliance to manufacture
plasmid DNA for Phase III trials and commercial supply


Keele, UK, 4 May 2005 - Cobra Biomanufacturing Plc (AIM:CBF.L), the
international manufacturer of biopharmaceuticals and Amsterdam Netherlands,
Synco BioPartners, a leading, contract manufacturing organization, announce they
have formed an alliance to manufacture plasmid DNA for Phase III trials and
commercial supply.

Under the terms of the agreement, Synco has acquired the license to Cobra's
intellectual property rights in the pDNA manufacturing process. This will enable
Synco to manufacture pDNA for both Phase III studies and for commercial supply.
Cobra will continue to offer preclinical, Phase I and Phase II pDNA manufacture.

Synco and Cobra have also agreed to collaborate in the marketing of their pDNA
manufacturing services and to collaborate in providing a first class, integrated
service to potential customers.

Thatcher, Chief Executive, Cobra Biomanufacturing said: "Cobra is proud to
form this important alliance with Synco BioPartners, "Synco is a leading
manufacturer with a licensed facility and an impressive track record in the
production of large-scale recombinant biopharmaceuticals and vaccines for
clinical trials and market supply. Synco has immense manufacturing strengths,
which truly complement Cobra's capabilities in development and IP, making them
an ideal partner."

Pierre Warffemius, CEO of Synco BioPartners B.V. added: " This agreement
leverages our position as a leading CMO in the biopharmaceutical market. We look
forward to a very productive collaboration with Cobra, who are a recognized
leader in the plasmid DNA market and has impressive IP. I believe there are
great synergies between their expertise in pDNA and our specialist, large-scale
manufacturing capabilities and I look forward to offering customers a first
class service".

RNS Number:6446M
Cobra Bio-Manufacturing PLC
24 May 2005

For Immediate Release 24 May 2005

COBRA BIOMANUFACTURING PLC

COBRA SIGNS AGREEMENT WITH INTROGEN THERAPEUTICS FOR MANUFACTURING SERVICES

Keele, UK: Cobra Biomanufacturing plc (AIM: CBF), the international manufacturer
of biopharmaceuticals, today announces an agreement with Introgen Therapeutics,
Inc. (NASDAQ: INGN) for production services.

Cobra will use its expertise in the development of DNA manufacturing strategies
and analytical development to provide GMP manufacturing services for one of
Introgen's clinical stage programs. Financial terms of the agreement were not
disclosed.

David Thatcher, Chief Executive of Cobra, said: "We very much look forward to
helping to provide the manufacturing needs of another US customer. Cobra is
delighted to have the opportunity to apply its experience to one of Introgen's
innovative products now in development. This agreement potentially covers
production of multiple batches of product over the next few years and can add
significant value to Cobra's income stream "

Dr. Peter Clarke, Introgen's Vice President for Production and Technical
Processes, added: "We look forward to working with Cobra as we expand our
programs to include new areas of therapeutic DNA product development. We
believe international relationships can enhance our corporate mission and expand
product development opportunities."


Notes for Editors

About Cobra Biomanufacturing

Cobra Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products. Cobra was
the first company to develop GMP (Good Manufacturing Practice) standard DNA
manufacture in Europe, with specific expertise in DNA medicines. A range of
unique, patented technologies, underpins this revenue generating business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange
in June 2002 raising #7 million and raised a further #5.25 million in May 2003
in order to further expand capacity in Oxford UK.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a leading developer of biopharmaceutical products
designed to induce therapeutic protein expression using non-integrating gene
agents for the treatment of cancer and other diseases. Introgen maintains
integrated research, development, manufacturing, clinical and regulatory
departments and operates a commercial-scale, CGMP manufacturing facility.

This information is provided by RNS
The company news service from the London Stock Exchange

Haven't followed Cobra really so not up with its history. But I am wondering why its been falling and continues to fall on apparently good news? Was more expected?

Cheers, Madison

After the recent dip in SP a welcome rise today.
On the 6th June Fidelity International notified the company stating they owned 701,900 share , 3.60 per cent.Given also that Evil holds a long position in Cobra i am hoping for a rise back to the 70p level that we recently saw.
DB66

A nice rise up today on the news that the interim results for six months ended 31st March will be announced on Thursday 30th June and not Tuesday 5th July as previously stated.

DB66

Huge drop today to 47p...looks like more downside on the way.

Time to BUY!!! added another 14K worth today.

Looks like some expansion may be going on at Cobra, they are advertising for at least eleven new staff at Oxford and Keele in the November 18th issue of New Scientist. Note use of plural/singular for the production scientist posts.

OXFORD:
Team Leader Microbiology,
Microbiologist,
QA Officer,
QC Analytical Scientist,
Team Leader Upstream Processing,
Team Leader Downstream Processing,
Senior Production Scientist(s),
Production Scientists(s).

KEELE FACILITY:
QC Team Leader,
GMP Production Supervisor for Microbial fermentation,
Senior Research Molecular Biologist.
copied from the other side

The big question is just how big a PROFIT we have made this year.
dyor

Little interest here, but the trend is down since earlier 2007 - and the GSK issue is bad news. although I suspect the sp reaction is overdone as they weren't banking on this work....it's not like your No1 customer has left suddenly.
Don't know what the trend is saying, though any ideas?
Anyone?

A year later and no comments!

Grief - Look at the SP fall.
Er, just what's up?

Ah Funding issues. . . . . well, we can expect a huge dilution at about 10p-ish I'm guessing.....oh deary....

Does the UK produce any good Executives?


EDIT - read latest RNS - it seems the Dixons have (with others) bought shares at 5p recently increasing their % but by arrangement they don't have to mount a full takeover.
This is a BAD scenario, IMHO.......did any other investors miss-out. Cheated, shafted come to mind....Ouch!
All IMHO - DYOR.

The directors appear to have benefitted from this emergency placing; why not a full rights issue to give all shareholders a chance.

Some qusetions need to be asked at the EGM

The company is encouraging all shareholders to attend the EGM. Why?
The directors assume that shareholders can get the time off / are willing to pay the travel costs.

I wonder, but does this demonstrate that a knocked company will never return?
The sp was 1.38 when IC suggested "Buy" [ I thought it had already had a good run and waited ]- and within a few weeks it was down to 82p - and then fell to 36p, followed by 24/28 - this slowly recovered for about a year, then once beyond 60p it started to fall again = just look at it now . . . . a pathetic share-price demonstrates the Market's belief in these Execs.
+Furthermore it looks like the Dixons are mounting a takeover.....(but then I could be wrong.)....
EGM - who will attend, be realistic!
-DYOR-

c. 12% dip today - looks worse than it is, I'm guessing this is the drift towards the value placed on the shares by others......there being a tendency for MM's to drop the price until the Market "forgets" the woes.

I read they have got the 1.2m - but how long will this last?
Could it last 3-months? - OR - 6-months, even?
Without a decent order ( being invoiced!), they have only the promise of an order....(The one ann. in Jan08 if memory serves). That is some way off from delivery, as they need to refurbish their plant ( Yikes!).....to meet the new demands - - - looks like the Buyer was very generous to give [CBF] an order they didn't have the capability (then?), to deliver.
Oh well, at least we know the background to the fall.
(- er, unless anyone has another theory...).

EDIT. 19Aug08- Pethris - did anything happen recently? - sp up 5% today (5p to buy)...I've almost lost interest....

Yes how long will the cash last you rightly ask. Another announcement today - hurrah - but of what substance?
Shareholders feel extremely aggrieved-the situation is pathetic-how much can the Dixons take before they exit - in which case how and when????????

In view of Seymour Pierce's holding have they invited Cobra to present at Growth Investors' Show today?

-Growth Show 2008 - don't think they were there.-
Big drop today, despite some share transfers (earlier this month) by Director D.Thatcher (DYOR). . . . a neutral position, IMHO.
But today's fall is not good - whatever the reason, looking like a (single) Sell of 250k
. . . . . . leaving investors with Sell= 3p, Buy=4p
that's a poor spread!